These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18450596)

  • 1. Oral supplementation of lutein/zeaxanthin and omega-3 long chain polyunsaturated fatty acids in persons aged 60 years or older, with or without AMD.
    Huang LL; Coleman HR; Kim J; de Monasterio F; Wong WT; Schleicher RL; Ferris FL; Chew EY
    Invest Ophthalmol Vis Sci; 2008 Sep; 49(9):3864-9. PubMed ID: 18450596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.
    Age-Related Eye Disease Study 2 Research Group
    JAMA; 2013 May; 309(19):2005-15. PubMed ID: 23644932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of long-chain ω-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.
    ; Bonds DE; Harrington M; Worrall BB; Bertoni AG; Eaton CB; Hsia J; Robinson J; Clemons TE; Fine LJ; Chew EY
    JAMA Intern Med; 2014 May; 174(5):763-71. PubMed ID: 24638908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Macular xanthophylls and ω-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: a randomized trial.
    Arnold C; Winter L; Fröhlich K; Jentsch S; Dawczynski J; Jahreis G; Böhm V
    JAMA Ophthalmol; 2013 May; 131(5):564-72. PubMed ID: 23519529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Dietary Supplementation With Lutein, Zeaxanthin, and ω-3 on Macular Pigment: A Randomized Clinical Trial.
    Korobelnik JF; Rougier MB; Delyfer MN; Bron A; Merle BMJ; Savel H; Chêne G; Delcourt C; Creuzot-Garcher C
    JAMA Ophthalmol; 2017 Nov; 135(11):1259-1266. PubMed ID: 28973076
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long term effects of lutein, zeaxanthin and omega-3-LCPUFAs supplementation on optical density of macular pigment in AMD patients: the LUTEGA study.
    Dawczynski J; Jentsch S; Schweitzer D; Hammer M; Lang GE; Strobel J
    Graefes Arch Clin Exp Ophthalmol; 2013 Dec; 251(12):2711-23. PubMed ID: 23695657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Age-Related Eye Disease Study 2 (AREDS2): study design and baseline characteristics (AREDS2 report number 1).
    ; Chew EY; Clemons T; SanGiovanni JP; Danis R; Domalpally A; McBee W; Sperduto R; Ferris FL
    Ophthalmology; 2012 Nov; 119(11):2282-9. PubMed ID: 22840421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Omega-3 Fatty Acids, Lutein/Zeaxanthin, or Other Nutrient Supplementation on Cognitive Function: The AREDS2 Randomized Clinical Trial.
    Chew EY; Clemons TE; Agrón E; Launer LJ; Grodstein F; Bernstein PS;
    JAMA; 2015 Aug; 314(8):791-801. PubMed ID: 26305649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.
    ; Chew EY; Clemons TE; Sangiovanni JP; Danis RP; Ferris FL; Elman MJ; Antoszyk AN; Ruby AJ; Orth D; Bressler SB; Fish GE; Hubbard GB; Klein ML; Chandra SR; Blodi BA; Domalpally A; Friberg T; Wong WT; Rosenfeld PJ; Agrón E; Toth CA; Bernstein PS; Sperduto RD
    JAMA Ophthalmol; 2014 Feb; 132(2):142-9. PubMed ID: 24310343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.
    Chew EY; Clemons TE; Agrón E; Domalpally A; Keenan TDL; Vitale S; Weber C; Smith DC; Christen W;
    JAMA Ophthalmol; 2022 Jul; 140(7):692-698. PubMed ID: 35653117
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lutein/zeaxanthin for the treatment of age-related cataract: AREDS2 randomized trial report no. 4.
    ; Chew EY; SanGiovanni JP; Ferris FL; Wong WT; Agron E; Clemons TE; Sperduto R; Danis R; Chandra SR; Blodi BA; Domalpally A; Elman MJ; Antoszyk AN; Ruby AJ; Orth D; Bressler SB; Fish GE; Hubbard GB; Klein ML; Friberg TR; Rosenfeld PJ; Toth CA; Bernstein P
    JAMA Ophthalmol; 2013 Jul; 131(7):843-50. PubMed ID: 23645227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration.
    Ma L; Yan SF; Huang YM; Lu XR; Qian F; Pang HL; Xu XR; Zou ZY; Dong PC; Xiao X; Wang X; Sun TT; Dou HL; Lin XM
    Ophthalmology; 2012 Nov; 119(11):2290-7. PubMed ID: 22858124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No CFH or ARMS2 Interaction with Omega-3 Fatty Acids, Low versus High Zinc, or β-Carotene versus Lutein and Zeaxanthin on Progression of Age-Related Macular Degeneration in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report No. 18.
    van Asten F; Chiu CY; Agrón E; Clemons TE; Ratnapriya R; Swaroop A; Klein ML; Fan R; Chew EY;
    Ophthalmology; 2019 Nov; 126(11):1541-1548. PubMed ID: 31358387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-ranging study of lutein supplementation in persons aged 60 years or older.
    Rosenthal JM; Kim J; de Monasterio F; Thompson DJ; Bone RA; Landrum JT; de Moura FF; Khachik F; Chen H; Schleicher RL; Ferris FL; Chew EY
    Invest Ophthalmol Vis Sci; 2006 Dec; 47(12):5227-33. PubMed ID: 17122107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral Lutein Supplementation Enhances Macular Pigment Density and Contrast Sensitivity but Not in Combination With Polyunsaturated Fatty Acids.
    Wolf-Schnurrbusch UE; Zinkernagel MS; Munk MR; Ebneter A; Wolf S
    Invest Ophthalmol Vis Sci; 2015 Dec; 56(13):8069-74. PubMed ID: 26720458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Mortality with Ocular Diseases and Visual Impairment in the Age-Related Eye Disease Study 2: Age-Related Eye Disease Study 2 Report Number 13.
    ; Papudesu C; Clemons TE; Agrón E; Chew EY
    Ophthalmology; 2018 Apr; 125(4):512-521. PubMed ID: 29153456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foveal macular pigment dip in offspring of age-related macular degeneration patients is inversely associated with omega-3 index.
    Rutledge GA; Pratt SG; Richer SP; Huntjens B; Perry CB; Pratt G; Podella C
    BMC Ophthalmol; 2020 Dec; 20(1):473. PubMed ID: 33267825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma long-chain omega-3 polyunsaturated fatty acids and macular pigment in subjects with family history of age-related macular degeneration: the Limpia Study.
    Merle BMJ; Buaud B; Korobelnik JF; Bron A; Delyfer MN; Rougier MB; Savel H; Vaysse C; Creuzot-Garcher C; Delcourt C
    Acta Ophthalmol; 2017 Dec; 95(8):e763-e769. PubMed ID: 28271618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutrient supplementation with n3 polyunsaturated fatty acids, lutein, and zeaxanthin decrease A2E accumulation and VEGF expression in the retinas of Ccl2/Cx3cr1-deficient mice on Crb1rd8 background.
    Ramkumar HL; Tuo J; Shen DF; Zhang J; Cao X; Chew EY; Chan CC
    J Nutr; 2013 Jul; 143(7):1129-35. PubMed ID: 23677863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: a randomized, double-masked, placebo-controlled trial.
    Ma L; Dou HL; Huang YM; Lu XR; Xu XR; Qian F; Zou ZY; Pang HL; Dong PC; Xiao X; Wang X; Sun TT; Lin XM
    Am J Ophthalmol; 2012 Oct; 154(4):625-634.e1. PubMed ID: 22835510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.